Compare SOPH & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOPH | MGTX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 462.3M | 1.0B |
| IPO Year | 2021 | 2018 |
| Metric | SOPH | MGTX |
|---|---|---|
| Price | $7.40 | $10.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $9.75 | ★ $27.75 |
| AVG Volume (30 Days) | 651.2K | ★ 1.0M |
| Earning Date | 11-03-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | N/A | ★ 1.30 |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $23.24 | $314.19 |
| Revenue Next Year | $24.63 | N/A |
| P/E Ratio | ★ N/A | $8.08 |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $3.75 | $6.62 |
| 52 Week High | $8.98 | $15.35 |
| Indicator | SOPH | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.46 | 33.38 |
| Support Level | $4.58 | $8.84 |
| Resistance Level | $8.80 | $10.71 |
| Average True Range (ATR) | 0.48 | 0.58 |
| MACD | -0.14 | -0.05 |
| Stochastic Oscillator | 29.60 | 12.33 |
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.